Fiche publication
Date publication
décembre 2019
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIENOT Angélique
Tous les auteurs :
Hilmi M, Vienot A, Rousseau B, Neuzillet C
Lien Pubmed
Résumé
Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) display a poor prognosis with 5-year overall survival rates around 15%, all stages taken together. These primary liver malignancies are often diagnosed at advanced stages where therapeutic options are limited. Recently, immune therapy has opened new opportunities in oncology. Based on their high programmed death-ligand 1 expression and tumor-infiltrating lymphocytes, HCC and BTC are theoretically good candidates for immune checkpoint blockade. However, clinical activity of single agent immunotherapy appears limited to a subset of patients, which is still ill-defined, and combinations are under investigation. In this review, we provide an overview of (i) the biological rationale for immunotherapies in HCC and BTC, (ii) the current state of their clinical development, and (iii) the predictive value of immune signatures for both clinical outcome and response to these therapies.
Mots clés
biliary tract cancers, checkpoint inhibitor, drug combination, hepatocellular carcinoma, immunology, tumor microenvironment
Référence
Cancers (Basel). 2019 Dec 27;12(1):
